A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00201 in Healthy Male and Female Volunteers
Latest Information Update: 08 Dec 2022
At a glance
- Drugs AUT 00201 (Primary)
- Indications Hearing disorders; Hearing loss; Schizophrenia
- Focus Adverse reactions; First in man
- Sponsors Autifony Therapeutics
Most Recent Events
- 13 Oct 2021 New source identified and integrated ISRCTN: Current Controlled Trials (18263497)
- 11 Oct 2021 Accural to date is 57 according to ISRCTN: Current Controlled Trials (18263497)
- 12 Jan 2021 Status changed from suspended to completed.